<p>Krilogy Financial LLC 在第二季度增持了 CRISPR Therapeutics AG（納斯達克股票代碼：CRSP）的持股，增幅達到 92.9%，根據該公司最近向證券交易委員會披露的信息。該公司在該時期購入額外的 10,050 股後，持有該公司股票 20,872 股。Krilogy Financial LLC 在最近一個季度結束時持有的 CRISPR Therapeutics 股票價值 1,127,000 美元。</p>
<p>獲取 <strong>CRISPR Therapeutics</strong> 警報：</p>
<ul>
<li>3 家股價下跌的製藥公司，有望迎來價格上漲的催化劑</li>
</ul>
<p>其他許多機構投資者最近也調整了他們對該公司的持股。Nordea Investment Management AB 在第一季度增持了 CRISPR Therapeutics 的持股，增幅為 40.8%。現在，Nordea Investment Management AB 持有該公司 148,700 股，價值 10,305,000 美元，上季度購入了 43,100 股。Congress Asset Management Co. MA 在第一季度增持了 CRISPR Therapeutics 的股份，增幅為 60.3%。現在，Congress Asset Management Co. MA 持有該公司 64,605 股，價值 4,403,000 美元，上季度購入了 24,303 股。PBCay One RSC Ltd 在第四季度購入了價值 10,329,000 美元的 CRISPR Therapeutics 新頭寸。Cetera Investment Advisers 在第一季度將其對 CRISPR Therapeutics 的持股增加了 451.3%。Cetera Investment Advisers 現在持有該公司 34,100 股，價值 2,324,000 美元，上季度購入了 27,915 股。最後，CWM LLC 在第二季度將其對 CRISPR Therapeutics 的持股增加了 11,871.1%。CWM LLC 現在持有該公司 22,386 股，價值 1,209,000 美元，上季度購入了 22,199 股。目前，69.20% 的股份由對沖基金和其他機構投資者持有。</p>
<h2>分析師設定新的價格目標</h2>
<p>一些分析師對該公司發表了意見。Robert W. Baird 將 CRISPR Therapeutics 的價格目標從 46.00 美元提高到 52.00 美元，並在 5 月 9 日星期四的研究報告中給予該公司 “中性” 評級。Rodman &amp; Renshaw 在 8 月 2 日星期五對 CRISPR Therapeutics 的股票進行了覆蓋。他們為該公司設定了 “買入” 評級和 90.00 美元的價格目標。Needham &amp; Company LLC 將 CRISPR Therapeutics 的目標價從 88.00 美元降至 84.00 美元，並在 8 月 6 日星期二的研究報告中為該公司設定了 “買入” 評級。巴克萊將 CRISPR Therapeutics 的目標價從 67.00 美元降至 59.00 美元，並在 8 月 6 日星期二的研究報告中為該股設定了 “等權重” 評級。最後，Guggenheim 在 6 月 28 日星期五的研究報告中重申了對 CRISPR Therapeutics 的 “中性” 評級。三位股票研究分析師給予該股 “賣出” 評級，八位給予 “持有” 評級，九位給予 “買入” 評級。根據 MarketBeat.com 的數據，該股目前的共識評級為 “持有”，平均目標價為 75.63 美元。</p>
<p><strong>閲讀我們對 CRSP 的最新分析</strong></p>
<h2>CRISPR Therapeutics 股價表現</h2>
<p>CRSP 股票週三交易時上漲 0.92 美元，報價 49.99 美元。該股交易量為 1,108,313 股，相比平均交易量 1,573,917 股有所下降。該公司的市值為 42.5 億美元，市盈率為-18.17，貝塔係數為 1.70。該股的五十日移動平均價格為 55.02 美元，兩百日移動平均價格為 61.96 美元。CRISPR Therapeutics AG 的 52 周最低價為 37.55 美元，最高價為 91.10 美元。</p>
<p>CRISPR Therapeutics（納斯達克股票代碼：CRSP - 獲取免費報告）於 8 月 5 日星期一發布了季度財報。該公司報告稱，該季度每股收益（EPS）為-1.49 美元，低於市場預期的-1.43 美元。該季度業務收入為 520 萬美元，而分析師預計為 12.31 億美元。與去年同期相比，該季度業務收入下降了 99.3%。分析師預計，CRISPR Therapeutics AG 在本財年將實現-5.52 美元的每股收益。</p>
<h2>內部人員活動</h2>
<p>另外，首席運營官 Julianne Bruno 於 6 月 21 日星期五出售了 3,366 股 CRISPR Therapeutics 股票。這些股票的平均價格為 56.09 美元，總交易額為 188,798.94 美元。在此次交易後，首席運營官現在持有公司 6,745 股，價值 378,327.05 美元。該交易已在提交給證券交易委員會的文件中披露，可在此鏈接處查看。內部人員持有該公司的股份佔公司股份的 4.10%。</p>
<h2>CRISPR Therapeutics 簡介（免費報告）</h2>
<p>CRISPR Therapeutics 是一家專注於利用其專有的 CRISPR/Cas9 平台開發用於治療嚴重疾病的轉型基因藥物的基因編輯公司。CRISPR/Cas9 是一種革命性的基因編輯技術，可以對基因組 DNA 進行精確、定向的改變。CRISPR Therapeutics 已在包括血紅蛋白病、腫瘤學、再生醫學和罕見疾病在內的廣泛疾病領域建立了治療項目組合。</p>
<h2>另請參閲</h2>
<ul>
<li>我們喜歡的五隻股票，比 CRISPR Therapeutics 更好</li>
<li>交易量異常的股票：如何實時找到交易量異常的股票</li>
<li>目標達成：第二季度盈利超出預期</li>
<li>突破性股票：它們是什麼以及如何識別它們</li>
<li>特斯拉的反彈剛剛開始嗎？為什麼您應該考慮購買</li>
<li>房地產投資信託基金是否應該在您的投資組合中佔一席之地？</li>
<li>斯坦利·德倫米勒的最新押注：MELI—您應該跟隨嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。在發佈之前，該故事經過了 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 特朗普正在發出警報（來自 Preserve Gold）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTI3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTI3"/></p>
<h2>現在是否值得投資 1,000 美元在 CRISPR 治療？</h2>
<p>在考慮投資 CRISPR 治療之前，您可能想要聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票...而 CRISPR 治療並不在名單上。</p>
<p>雖然 CRISPR 治療目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CRISPR治療

<p>Krilogy Financial LLC 在第二季度增加了對 CRISPR Therapeutics AG（NASDAQ:CRSP）的持股比例，增幅達 92.9%，收購了 10,050 股，使其總持股量達到 20,872 股，價值 12.7 萬美元。其他機構投資者也增加了他們的持股比例。分析師們提供了不同的目標價格和評級，共識評級為 “持有”，平均目標價格為 66.63 美元。儘管有交易活動，CRISPR 的股票季度每股虧損 0.49 美元，低於預期，因為收入與去年相比顯著下降</p>

<p>Krilogy Financial LLC grew its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 92.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 20,872 shares of the company's stock after purchasing an additional 10,050 shares during the period. Krilogy Financial LLC's holdings in CRISPR Therapeutics were worth $1,127,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Krilogy Financial LLC 在第二季度增持了 CRISPR Therapeutics AG（納斯達克股票代碼：CRSP）的持股，增幅達到 92.9%，根據該公司最近向證券交易委員會披露的信息。該公司在該時期購入額外的 10,050 股後，持有該公司股票 20,872 股。Krilogy Financial LLC 在最近一個季度結束時持有的 CRISPR Therapeutics 股票價值 1,127,000 美元。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<ul>
<li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>CRISPR Therapeutics</strong> 警報：</p>
<ul>
<li>3 家股價下跌的製藥公司，有望迎來價格上漲的催化劑</li>
</ul>
</div><p>A number of other institutional investors also recently modified their holdings of the business. Nordea Investment Management AB grew its holdings in CRISPR Therapeutics by 40.8% during the 1st quarter. Nordea Investment Management AB now owns 148,700 shares of the company's stock valued at $10,305,000 after buying an additional 43,100 shares in the last quarter. Congress Asset Management Co. MA grew its position in shares of CRISPR Therapeutics by 60.3% during the 1st quarter. Congress Asset Management Co. MA now owns 64,605 shares of the company's stock valued at $4,403,000 after purchasing an additional 24,303 shares in the last quarter. PBCay One RSC Ltd bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth $10,329,000. Cetera Investment Advisers increased its stake in CRISPR Therapeutics by 451.3% in the 1st quarter. Cetera Investment Advisers now owns 34,100 shares of the company's stock worth $2,324,000 after acquiring an additional 27,915 shares during the last quarter. Finally, CWM LLC raised its stake in CRISPR Therapeutics by 11,871.1% in the second quarter. CWM LLC now owns 22,386 shares of the company's stock valued at $1,209,000 after purchasing an additional 22,199 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他許多機構投資者最近也調整了他們對該公司的持股。Nordea Investment Management AB 在第一季度增持了 CRISPR Therapeutics 的持股，增幅為 40.8%。現在，Nordea Investment Management AB 持有該公司 148,700 股，價值 10,305,000 美元，上季度購入了 43,100 股。Congress Asset Management Co. MA 在第一季度增持了 CRISPR Therapeutics 的股份，增幅為 60.3%。現在，Congress Asset Management Co. MA 持有該公司 64,605 股，價值 4,403,000 美元，上季度購入了 24,303 股。PBCay One RSC Ltd 在第四季度購入了價值 10,329,000 美元的 CRISPR Therapeutics 新頭寸。Cetera Investment Advisers 在第一季度將其對 CRISPR Therapeutics 的持股增加了 451.3%。Cetera Investment Advisers 現在持有該公司 34,100 股，價值 2,324,000 美元，上季度購入了 27,915 股。最後，CWM LLC 在第二季度將其對 CRISPR Therapeutics 的持股增加了 11,871.1%。CWM LLC 現在持有該公司 22,386 股，價值 1,209,000 美元，上季度購入了 22,199 股。目前，69.20% 的股份由對沖基金和其他機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>Several analysts have weighed in on the company. Robert W. Baird boosted their price objective on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, May 9th. Rodman &amp; Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a &#34;buy&#34; rating and a $90.00 price objective for the company. Needham &amp; Company LLC lowered their target price on CRISPR Therapeutics from $88.00 to $84.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, August 6th. Barclays reduced their target price on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Tuesday, August 6th. Finally, Guggenheim reiterated a &#34;neutral&#34; rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $75.63.</p>
<ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><p>一些分析師對該公司發表了意見。Robert W. Baird 將 CRISPR Therapeutics 的價格目標從 46.00 美元提高到 52.00 美元，並在 5 月 9 日星期四的研究報告中給予該公司 “中性” 評級。Rodman &amp; Renshaw 在 8 月 2 日星期五對 CRISPR Therapeutics 的股票進行了覆蓋。他們為該公司設定了 “買入” 評級和 90.00 美元的價格目標。Needham &amp; Company LLC 將 CRISPR Therapeutics 的目標價從 88.00 美元降至 84.00 美元，並在 8 月 6 日星期二的研究報告中為該公司設定了 “買入” 評級。巴克萊將 CRISPR Therapeutics 的目標價從 67.00 美元降至 59.00 美元，並在 8 月 6 日星期二的研究報告中為該股設定了 “等權重” 評級。最後，Guggenheim 在 6 月 28 日星期五的研究報告中重申了對 CRISPR Therapeutics 的 “中性” 評級。三位股票研究分析師給予該股 “賣出” 評級，八位給予 “持有” 評級，九位給予 “買入” 評級。根據 MarketBeat.com 的數據，該股目前的共識評級為 “持有”，平均目標價為 75.63 美元。</p>
</div><p><strong>Read Our Latest Analysis on CRSP</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 CRSP 的最新分析</strong></p>
</div><h2>CRISPR Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 股價表現</h2>
</div><p>Shares of CRSP traded up $0.92 during trading hours on Wednesday, hitting $49.99. The stock had a trading volume of 1,108,313 shares, compared to its average volume of 1,573,917. The firm has a market capitalization of $4.25 billion, a PE ratio of -18.17 and a beta of 1.70. The stock has a fifty day moving average price of $55.02 and a 200 day moving average price of $61.96. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10.</p>
<ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><p>CRSP 股票週三交易時上漲 0.92 美元，報價 49.99 美元。該股交易量為 1,108,313 股，相比平均交易量 1,573,917 股有所下降。該公司的市值為 42.5 億美元，市盈率為-18.17，貝塔係數為 1.70。該股的五十日移動平均價格為 55.02 美元，兩百日移動平均價格為 61.96 美元。CRISPR Therapeutics AG 的 52 周最低價為 37.55 美元，最高價為 91.10 美元。</p>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. During the same period in the previous year, the company earned ($0.98) earnings per share. The business's revenue for the quarter was down 99.3% compared to the same quarter last year. As a group, analysts anticipate that CRISPR Therapeutics AG will post -5.52 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CRISPR Therapeutics（納斯達克股票代碼：CRSP - 獲取免費報告）於 8 月 5 日星期一發布了季度財報。該公司報告稱，該季度每股收益（EPS）為-1.49 美元，低於市場預期的-1.43 美元。該季度業務收入為 520 萬美元，而分析師預計為 12.31 億美元。與去年同期相比，該季度業務收入下降了 99.3%。分析師預計，CRISPR Therapeutics AG 在本財年將實現-5.52 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部人員活動</h2>
</div><p>In other news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares in the company, valued at $378,327.05. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>另外，首席運營官 Julianne Bruno 於 6 月 21 日星期五出售了 3,366 股 CRISPR Therapeutics 股票。這些股票的平均價格為 56.09 美元，總交易額為 188,798.94 美元。在此次交易後，首席運營官現在持有公司 6,745 股，價值 378,327.05 美元。該交易已在提交給證券交易委員會的文件中披露，可在此鏈接處查看。內部人員持有該公司的股份佔公司股份的 4.10%。</p>
</div><h2>CRISPR Therapeutics Profile (Free Report)</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 簡介（免費報告）</h2>
</div><p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 是一家專注於利用其專有的 CRISPR/Cas9 平台開發用於治療嚴重疾病的轉型基因藥物的基因編輯公司。CRISPR/Cas9 是一種革命性的基因編輯技術，可以對基因組 DNA 進行精確、定向的改變。CRISPR Therapeutics 已在包括血紅蛋白病、腫瘤學、再生醫學和罕見疾病在內的廣泛疾病領域建立了治療項目組合。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Target Hits the Mark: Q2 Earnings Exceed Expectations</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Is Tesla’s Rebound Just Starting? Why You Should Consider Buying</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>Stanley Druckenmiller's Latest Bet: MELI—Should You Follow Suit?</li>
</ul>
<div class="lb-trans"><h2>另請參閲</h2>
<ul>
<li>我們喜歡的五隻股票，比 CRISPR Therapeutics 更好</li>
<li>交易量異常的股票：如何實時找到交易量異常的股票</li>
<li>目標達成：第二季度盈利超出預期</li>
<li>突破性股票：它們是什麼以及如何識別它們</li>
<li>特斯拉的反彈剛剛開始嗎？為什麼您應該考慮購買</li>
<li>房地產投資信託基金是否應該在您的投資組合中佔一席之地？</li>
<li>斯坦利·德倫米勒的最新押注：MELI—您應該跟隨嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。在發佈之前，該故事經過了 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Trump is sounding the alarm (From Preserve Gold)(Ad)</p>
<div class="lb-trans"><p>→ 特朗普正在發出警報（來自 Preserve Gold）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTI3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8927&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in CRISPR Therapeutics right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元在 CRISPR 治療？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 CRISPR 治療之前，您可能想要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票...而 CRISPR 治療並不在名單上。</p>
</div><p>While CRISPR Therapeutics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CRISPR 治療目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Krilogy Financial LLC 收購了 CRISPR 治療公司（納斯達克股票代碼：CRSP）的 10,050 股股票